Psoriasis is a complex, multigenic immune/inflammatory-mediated disorder that variably
affects the skin, nails, and joints. In September 2009, ustekinumab (Stelara®), a monoclonal …

Ustekinumab (Stelara®) is a human monoclonal antibody that binds to the shared p40
subunit of interleukin (IL)-12 and IL-23, blocking signalling of their cognate receptors. It is …

Psoriasis is a chronic inflammatory disorder characterized by T cell dysregulation and a
chronic inflammatory infiltrate within the epidermis. Several cytokines play an important role …

Ustekinumab, which is approved for the treatment of moderate to severe psoriasis, has been
shown in phase II clinical trials to be efficacious in controlling the signs and symptoms of …

Ustekinumab (Stelara™) is a human monoclonal antibody that binds to the p40 subunit
common to both interleukin (IL)-12 and IL-23. It is indicated in the US for use in adult patients …

Chronic plaque psoriasis is a systemic disease affecting over 3% of the population, and
many patients are unsatisfied with their current treatment regimen. With advances in …

Purpose Advances in the treatment of moderate-to-severe plaque psoriasis, including new
biological agents and related drugs, are reviewed. Summary Most patients with psoriasis …

The pathogenesis of psoriasis is unknown, although it is generally accepted that this chronic
inflammatory skin disorder is a complex autoimmune condition similar to other T-cell …

Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging
in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a …

ABSTRACT Introduction: Psoriasis (PsO) is an inflammatory disorder characterized by
proliferation of keratinocytes, and it may be associated with a systemic inflammatory articular …